H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HUTCHMED (China) Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Cash from Investing Activities
$19.4m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Cash from Investing Activities
-HK$515.7m
CAGR 3-Years
27%
CAGR 5-Years
34%
CAGR 10-Years
4%
S
SSY Group Ltd
HKEX:2005
Cash from Investing Activities
-HK$662.8m
CAGR 3-Years
-31%
CAGR 5-Years
10%
CAGR 10-Years
4%
U
United Laboratories International Holdings Ltd
HKEX:3933
Cash from Investing Activities
-ÂĄ1.6B
CAGR 3-Years
-56%
CAGR 5-Years
-21%
CAGR 10-Years
-6%
Sino Biopharmaceutical Ltd
HKEX:1177
Cash from Investing Activities
-ÂĄ757m
CAGR 3-Years
58%
CAGR 5-Years
26%
CAGR 10-Years
5%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Cash from Investing Activities
-HK$5.8B
CAGR 3-Years
-48%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
23.8B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Cash from Investing Activities?
Cash from Investing Activities
19.4m USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Cash from Investing Activities amounts to 19.4m USD.

What is HUTCHMED (China) Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-26%

Back to Top